FrancophonIA/ELRC3.0 huggingface dataset:
English: In HIV infected patients, in a 144-week controlled clinical study that compared tenofovir disoproxil with stavudine in combination with lamivudine and efavirenz in antiretroviral-naïve adult patients, small decreases in bone mineral density (BMD) of the hip and spine were observed in both treatment groups.
Croatian: U 144-tjednom kontroliranom kliničkom ispitivanju u bolesnika inficiranih HIV-om u kojemu je uspoređivan tenofovirdizoproksil sa stavudinom u kombinaciji s lamivudinom i efavirenzom u odraslih bolesnika koji prethodno nisu bili liječeni antiretrovirusnim lijekovima, u obje su liječene skupine zapažena mala smanjenja mineralne gustoće (engl. bone mineral density, BMD) kosti kuka i kralježnice.
English: One hundred forty-one and 139 adult subjects were randomised to a tenofovir disoproxil and emtricitabine plus tenofovir disoproxil treatment arm, respectively.
Croatian: Stotinu četrdeset jedan i 139 odraslih ispitanika bili su randomizirani u skupinu koja je bila liječena tenofovirdizoproksilom, odnosno u skupinu koja je bila liječena emtricitabinom i tenofovirdizoproksilom.
English: INFORMATION IN BRAILLE Viread 123 mg [Outer packaging only]
Croatian: Viread 123 mg [Samo na vanjskom pakiranju]
English: The co-primary safety endpoints were discontinuation due to an adverse event and confirmed increase in serum creatinine ≥ 0.5 mg/dl or confirmed serum phosphate of < 2 mg/dl.
Croatian: Ko-primarne mjere ishoda za sigurnost bile su prekid liječenja zbog nuspojave i potvrđenog porasta kreatinina u serumu za ≥ 0,5 mg/dl ili potvrđeni fosfat u serumu
English: Viread should be taken once daily, orally with food.
Croatian: Viread potrebno je uzimati peroralno s hranom, jedanput na dan.
English: Forty-three percent of patients had baseline viral loads > 100,000 copies/ml and 39% had CD4 cell counts < 200 cells/ml.
Croatian: > 100.000 kopija/ml, a 39% imalo je broj CD4 stanica < 200 stanica/ml.
English: HIV-1 clinical studies: Assessment of adverse reactions for tenofovir disoproxil is based on safety data from clinical studies and post-marketing experience.
Croatian: Klinička ispitivanja HIV-1: Procjena nuspojava tenofovirdizoproksila temelji se na sigurnosnim podacima prikupljenima u kliničkim ispitivanjima i razdoblju nakon stavljanja lijeka u promet.
English: • Contact your child's doctor before your child restarts taking Viread tablets.
Croatian: • Obratite se liječniku Vašeg djeteta prije nego što ponovno počne uzimati tablete Viread.
English: Therefore, clinical response to treatment and renal function should be closely monitored (see sections 4.4 and 5.2).
Croatian: Zbog toga je nužno pažljivo pratiti klinički odgovor na liječenje i funkciju bubrega (vidjeti dijelove 4.4 i 5.2).
English: Please refer to the Summary of Product Characteristics for Viread 33 mg/g granules.
Croatian: Molimo pročitajte sažetke opisa svojstava lijeka za Viread 33 mg/g granule.
English: Subjects with a high baseline CPT score were at higher risk of developing serious adverse events (see section 4.4).
Croatian: Ispitanici s visokim početnim CPT rezultatom imali su veći rizik od razvoja ozbiljnih štetnih događaja
English: Due to limitations of the study, a benefit of tenofovir disoproxil over placebo was not demonstrated based on plasma HIV-1 RNA levels at week 24.
Croatian: Zbog ograničenja ispitivanja nije se dokazala korist od tenofovirdizoproksila u usporedbi s placebom na temelju razina
English: HIV-1 infection
Croatian: HIV-1 infekcije.
English: The following side effects are very common (these can affect at least 10 in every 100 patients):
Croatian: Sljedeće nuspojave su vrlo česte (mogu se javiti u najmanje 10 na svakih 100 bolesnika):
English: The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and 3 bottles of 30 film-coated tablets.
Croatian: Dostupne su sljedeće veličine pakiranja: vanjske kartonske kutije koje sadrže 1 bocu s 30 filmom obloženih tableta i 3 boce s 30 filmom obloženih tableta.
English: Renal failure, renal impairment, elevated creatinine, hypophosphataemia and proximal tubulopathy (including Fanconi syndrome) have been reported with the use of tenofovir disoproxil in clinical practice (see section 4.8).
Croatian: zabilježeno je zatajenje bubrega, oštećenje funkcije bubrega, povišen kreatinin, hipofosfatemija i proksimalna tubulopatija (uključujući Fanconijev sindrom) (vidjeti dio 4.8).
English: Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes.
Croatian: Nakon toga konstitucijski izraženi stanični enzimi pretvaraju tenofovir u djelatni metabolit, tenofovirdifosfat, koji obavezno završava lanac.
English: • Contact your doctor before you restart taking Viread granules.
Croatian: • Obratite se liječniku prije nego što ponovno počnete uzimati granule Viread.
English: Renal safety with tenofovir has only been studied to a very limited degree in adult patients with impaired renal function (creatinine clearance < 80 ml/min).
Croatian: Sigurnost primjene tenofovira za bubrege ispitana je u vrlo ograničenom stupnju samo u odraslih bolesnika s oštećenjem funkcije bubrega (klirens kreatinina < 80 ml/min).
English: Co-administration of other medicinal products - Viread should not be administered concomitantly with other medicinal products containing tenofovir disoproxil or tenofovir alafenamide.
Croatian: Istovremena primjena drugih lijekova - Viread se ne smije davati zajedno s drugim lijekovima koji sadrže tenofovirdizoproksil ili tenofoviralafenamid.
English: Response to treatment with tenofovir disoproxil was also similar in subjects who were HBeAg-negative compared with those who were HBeAg-positive at baseline with 77% (43/56) HBeAg-positive and 75.0% (3/4) HBeAg-negative subjects achieving HBV DNA < 400 copies/mL (69 IU/mL) at Week 48.
Croatian: Odgovor na liječenje tenofovirdizoproksilom također je bio sličan u početno HBeAg negativnih i HBeAg pozitivnih ispitanika sa 77% (43/56) HBeAg pozitivnih i 75,0% (3/4) HBeAg negativnih ispitanika koji su postigli HBV DNK < 400 kopija/ml (69 IU/ml) u 48. tjednu.
English: Viread 33 mg/g granules are indicated for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with:
Croatian: Viread 33 mg/g granule indicirane su za liječenje kroničnog hepatitisa B u odraslih bolesnika u kojih primjena doza u krutom obliku nije prikladna s:
English: • compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels or histological evidence of moderate to severe inflammation and/or fibrosis.
Croatian: • kompenziranom bolešću jetre i dokazom imunološki aktivne bolesti, tj. aktivnom replikacijom virusa i trajno povišenim razinama ALT-a u serumu ili histološki dokazanom umjerenom do teškom upalom i/ili fibrozom.
English: The EC50 values for tenofovir were in the range of 0.14 to 1.5 µmol/l, with CC50 (50% cytotoxicity concentration) values > 100 µmol/l.
Croatian: do 1,5 µmol/l uz vrijednosti CC50 (50% citotoksične koncentracije) > 100 µmol/l.
English: Tolerability failure (permanent discontinuation of study drug due to a treatment emergent AE) n (%)
Croatian: Neuspjeh podnošljivosti (trajni prekid ispitivanja lijeka zbog nuspojave)
English: Normal ALT ≥ 2 point decrease in CPT from baseline n (%)
Croatian: ≥ 2 boda od početne vrijednosti n (%)
English: In adults, the demonstration of the benefit of Viread in HIV-1 infection is based on results of one study in treatment-naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).
Croatian: Dokaz uspješnosti Vireada u liječenju odraslih s infekcijom virusom HIV-1 temelji se na rezultatima jednog ispitivanja u prethodno neliječenih bolesnika, uključujući bolesnike s visokim virusnim opterećenjem (> 100.000 kopija/ml) i ispitivanja u kojima je Viread dodan stabilnoj osnovnoj terapiji
English: In study GS-US-104-0352, 8 out of 89 paediatric patients (9.0%) exposed to tenofovir disoproxil discontinued study drug due to renal adverse events.
Croatian: U ispitivanju GS-US-104-0352, 8 od 89 pedijatrijskih bolesnika (9,0 %) izloženih tenofovirdizoproksilu prekinulo je uzimanje ispitivanog lijeka zbog štetnih događaja povezanih s bubrezima.
English: No data are available on which to make a dose recommendation for patients over the age of 65 years (see section 4.4).
Croatian: Ne postoje podaci na osnovi kojih bi se mogla preporučiti doza za bolesnike starije od 65 godina
English: Bone Mineral Density (BMD) data from Study GS-US-174-0144 are summarized in Table 9:
Croatian: Podaci o mineralnoj gustoći kostiju (BMD) iz ispitivanja GS-US-174-0144 sažeto su navedeni u Tablici 9:
English: In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your child's hepatitis.
Croatian: U nekih se bolesnika s uznapredovalom bolešću jetre ili cirozom jetre ne preporučuje prekid liječenja, jer to može dovesti do pogoršanja hepatitisa Vašeg djeteta.
English: If your child throws up less than 1 hour after taking Viread, give your child another tablet.
Croatian: Ako je Vaše dijete povraćalo u razmaku manjem od 1 sata nakon što je uzelo Viread, dajte mu drugu tabletu.
English: The mean (%CV) tenofovir Cmax and AUC0-∞ values were 223 (34.8%) ng/ml and 2,050 (50.8%) ng·h/ml, respectively, in normal subjects compared with 289 (46.0%) ng/ml and 2,310 (43.5%) ng·h/ml in subjects with moderate hepatic impairment, and 305 (24.8%) ng/ml and 2,740 (44.0%) ng·h/ml in subjects with severe hepatic impairment.
Croatian: U normalnih ispitanika srednje vrijednosti (%CV) Cmax i AUC0-∞ tenofovira bile su 223 (34,8%) ng/ml odnosno 2.050 (50,8%) ng·h/ml, u usporedbi s 289 (46,0%) ng/ml i 2.310 (43,5%) ng·h/ml u ispitanika s umjerenim oštećenjem funkcije jetre, te 305 (24,8%) ng/ml i 2.740 (44,0%) ng·h/ml u ispitanika s teškim oštećenjem funkcije jetre.
English: • Do not give Viread if your child is already taking other medicines containing tenofovir disoproxil or tenofovir alafenamide.
Croatian: • Nemojte davati Viread Vašem djetetu ako već uzima druge lijekove koji sadrže tenofovirdizoproksil ili tenofoviralafenamid.
English: The potential risks and benefits associated with co-administration of ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir with tenofovir disoproxil given in conjunction with a boosted HIV protease inhibitor (e.g. atazanavir or darunavir) should be considered, particularly in patients at increased risk of renal dysfunction.
Croatian: Potrebno je razmotriti moguće rizike i koristi povezane s istovremenom primjenom ledipasvira/sofosbuvira, sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/voksilaprevira s tenofovirdizoproksilom danim zajedno s pojačanim inhibitorom HIV proteaze (npr. atazanavir ili darunavir), osobito u bolesnika pod povećanim rizikom od poremećaja funkcije bubrega.
English: b Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score.
Croatian: b Poboljšanje na Knodellovoj ljestvici nekroinflamatorne aktivnosti za najmanje 2 boda bez pogoršanja rezultata na Knodellovoj ljestvici fibroze.
English: Pharmacokinetic parameters of tenofovir were determined following administration of a single dose of tenofovir disoproxil 245 mg to 40 non-HIV, non-HBV infected adult patients with varying degrees of renal impairment defined according to baseline creatinine clearance (CrCl) (normal renal function when CrCl > 80 ml/min; mild with CrCl = 50-79 ml/min; moderate with CrCl = 30-49 ml/min and severe with CrCl = 10-29 ml/min).
Croatian: Oštećenje funkcije bubrega Farmakokinetički parametri tenofovira određeni su nakon primjene jednokratne doze tenofovirdizoproksila od 245 mg u 40 odraslih bolesnika koji nisu bili zaraženi virusom HIV-a a ni virusom HBV-a, s različitim stupnjevima oštećenja funkcije bubrega, definiranima prema početnoj vrijednosti klirensa kreatinina (CrCl) (normalna funkcija bubrega kada je CrCl > 80 ml/min; blago oštećenje kod CrCl = 50-79 ml/min; umjereno oštećenje kod CrCl = 30-49 ml/min i teško oštećenje kod CrCl = 10-29 ml/min).
English: Subjects must have been naïve to tenofovir disoproxil, with HBV DNA > 105 copies/mL (~ 4.2 log10 IU/mL) and ALT >1.5 × the upper limit of normal (ULN) at screening.
Croatian: Ispitanici nisu smjeli biti prethodnoi liječeni tenofovirdisoproksilom, morali su imati razinu HBV DNK > 105 kopija/ml (~ 4,2 log10 IU/ml) i ALT > 1,5 × gornja granica normale (GGN) na probiru.
English: Viread 33 mg/g granules are also a treatment for chronic hepatitis B, an infection with HBV (hepatitis B virus).
Croatian: Viread 33 mg/g granule također se primjenjuju za liječenje kroničnog hepatitisa B, infekcije virusom hepatitisa B (HBV).
English: • That if bone abnormalities are detected or suspected then consultation with an endocrinologist and/or nephrologist should be obtained
Croatian: • Ako se otkriju ili se sumnja na abnormalnosti kostiju, da onda treba potražiti stručno mišljenje endokrinologa i/ili nefrologa.
English: If the patient vomits more than 1 hour after taking Viread they do not need to take another dose.
Croatian: Ako bolesnik povraća nakon više od 1 sata od uzimanja Vireada, nije potrebno uzeti još jednu dozu.
English: Viread 245 mg tablets are suitable for:
Croatian: Viread 245 mg tablete pogodne su za:
English: Baseline demographics were similar between the two treatment arms: At baseline, 52.5% of subjects were
Croatian: Početni demografski podaci bili su slični između dviju skupina liječenja: na početku je 52,5% ispitanika bilo HBeAg-negativno, 47,5% bilo
English: • Do not take Viread if you are already taking other medicines containing tenofovir disoproxil or tenofovir alafenamide.
Croatian: • Nemojte uzimati Viread ako već uzimate druge lijekove koji sadrže tenofovirdizoproksil ili tenofoviralafenamid.
English: Co-administration of tenofovir disoproxil and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Croatian: Ne preporučuje se istovremena primjena tenofovirdizoproksila i didanozina, jer rezultira 40-60%-tnim povećanjem sistemske izloženosti didanozinu što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
English: Viread 33 mg/g granules are also indicated for the treatment of chronic hepatitis B in paediatric patients2 to < 18 years of age for whom a solid dosage form is not appropriate with:
Croatian: Viread 33 mg/g granule također su indicirane za liječenje kroničnog hepatitisa B u pedijatrijskih bolesnika u dobi od 12 do < 18 godina u kojih primjena doza u krutom obliku nije prikladna s:
English: Therapy should be initiated by a physician experienced in the management of HIV infection and/or treatment of chronic hepatitis B.
Croatian: 4.2 Doziranje i način primjene Terapiju mora započeti liječnik s iskustvom u liječenju infekcije HIV-om i/ili liječenju kroničnog hepatitisa B.
English: In study GS-US-104-0352, 8 out of 89 paediatric patients (9.0%) exposed to tenofovir disoproxil (median tenofovir disoproxil exposure 331 weeks) discontinued study drug due to renal adverse events.
Croatian: U ispitivanju GS-US-104-0352, 8 od 89 pedijatrijskih bolesnika (9,0 %) izloženih tenofovirdizoproksilu (medijan izloženosti tenofovirdizoproksilu : 331 tjedan) prekinulo je uzimanje ispitivanog lijeka zbog štetnih događaja povezanih s bubrezima.
English: • That if serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving tenofovir disoproxil fumarate, renal function should be re-evaluated within one week.
Croatian: • Ako se u bilo kojeg pedijatrijskog bolesnika koji uzima tenofovirdizoproksilfumarat potvrdi da je fosfat u serumu < 3,0 mg/dl (0,96 mmol/l), bubrežnu funkciju treba ponovno procijeniti u roku od tjedan dana.
English: • Contact your doctor before you restart taking Viread tablets.
Croatian: • Obratite se liječniku prije nego što ponovno počnete uzimati tablete Viread.
English: There are limited clinical data with respect to the effect of tenofovir disoproxil on fertility.
Croatian: Klinički podaci o učinku tenofovirdizoproksila na plodnost su ograničeni.
English: Mechanism of action and pharmacodynamic effects Tenofovir disoproxil fumarate is the fumarate salt of the prodrug tenofovir disoproxil.
Croatian: Tenofovirdizoproksilfumarat jest fumaratna sol predlijeka tenofovirdizoproksila.
English: Compared with patients with normal renal function, the mean (%CV) tenofovir exposure increased from 2,185 (12%) ng·h/ml in subjects with CrCl > 80 ml/min to respectively 3,064 (30%) ng·h/ml, 6,009 (42%) ng·h/ml and 15,985 (45%) ng·h/ml in patients with mild, moderate and severe renal impairment.
Croatian: U usporedbi s bolesnicima s normalnom funkcijom bubrega srednja se vrijednost (% koeficijenta varijacije) izloženosti tenofoviru povećala s 2.185 (12%) ng·h/ml u ispitanika s CrCl > 80 ml/min na 3.064 (30%) ng·h/ml u bolesnika s blagim oštećenjem funkcije bubrega, 6.009 (42%) ng·h/ml u bolesnika s umjerenim oštećenjem bubrega i 15.985 (45%) ng·h/ml u bolesnika s teškim oštećenjem bubrežne funkcije.
English: In a paediatric study (GS-US-174-0115), 52 patients (including 6 patients with lamivudine resistance mutations at baseline) initially received blinded tenofovir disoproxil for up to 72 weeks and then 51/52 patients switched to open-label tenofovir disoproxil (tenofovir disoproxil-tenofovir disoproxil group).
Croatian: U pedijatrijskom ispitivanju (GS-US-174-0115), 52 bolesnika (uključujući 6 bolesnika s mutacijama za rezistenciju na lamivudin na početku) početno je slijepo primalo tenofovirdizoproksil do 72 tjedna, a potom je 51/52 bolesnika prebačeno na otvoreno liječenje tenofovirdizoproksilom (skupina tenofovirdizoproksil-tenofovirdizoproksil).
English: Severe renal impairment (creatinine clearance < 30 ml/min) and haemodialysis patients For patients unable to take the granule formulation of tenofovir disoproxil and with no alternative treatment available, prolonged dose intervals using the 245 mg film-coated tablets may be used as follows:
Croatian: Za bolesnike koji ne mogu uzimati tenofovirdizoproksil u obliku granula i bez dostupnog zamjenskog liječenja mogu se primjenjivati produženi intervali između doza 245 mg filmom obloženih tableta kako slijedi:
English: Each tablet contains 82 mg lactose (as monohydrate).
Croatian: Jedna tableta sadrži 82 mg laktoze (u obliku hidrata).
English: Viread 204 mg tablets are for use in children.
Croatian: Viread 204 mg tablete namijenjene su primjeni u djece.
English: As a general rule, it is recommended that HIV and HBV infected women do not breast-feed their infants in order to avoid transmission of HIV and HBV to the infant.
Croatian: Kao opće pravilo, preporučuje se da žene inficirane HIV-om a i HBV-om ne doje svoju dojenčad,
English: Viread should not be given to adolescents with existing kidney problems.
Croatian: Viread se ne smije davati adolescentima s bubrežnim tegobama.
English: rhabdomyolysis
Croatian: laktacidoza
English: It is recommended that renal function (creatinine clearance and serum phosphate) is assessed in all patients prior to initiating therapy with tenofovir disoproxil and that it is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors.
Croatian: Preporučuje se procijeniti funkciju bubrega (klirens kreatinina i fosfat u serumu) u svih bolesnika prije početka terapije tenofovirdizoproksilom i pratiti je nakon dva do četiri tjedna liječenja, nakon tri mjeseca liječenja i svakih tri do šest mjeseci nakon toga u bolesnika bez bubrežnih čimbenika rizika.
English: In study GS-US-174-0103 a significantly greater proportion of patients in the tenofovir disoproxil group than in the adefovir dipivoxil group had normalised ALT and achieved HBsAg loss at week 48 (see Table 4 below).
Croatian: U ispitivanju GS-US-174-0103 značajno veći udio bolesnika u skupini koja je dobivala tenofovirdizoproksil imao je normaliziranu razinu ALT-a u odnosu na skupinu bolesnika koja je dobivala adefovirdipivoksil te je nestanak HBsAG postignut u 48. tjednu (vidjeti tablicu 4 niže).
English: HBV DNA (%) < 400 copies/ml (< 69 IU/ml) ALT (%) Normalised ALTd
Croatian: HBV DNK (%) < 400 kopija/ml (< 69 IU/ml) ALT (%) normaliziran ALTd
English: If you accidentally take too many Viread tablets, you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects).
Croatian: Ako slučajno uzmete previše Viread tableta, možete imati povećani rizik od mogućih nuspojava ovog lijeka (pogledajte dio 4, Moguće nuspojave).
English: HBsAg loss/ seroconversion n k n n a Based upon Long Term Evaluation algorithm (LTE Analysis) - Patients who discontinued the study at any time prior to week 384 due to a protocol defined endpoint, as well as those completing week 384, are included in the denominator.
Croatian: 1/1n a Temelji se na algoritmu dugoročne promjene (LTE analiza) - Bolesnici koji su prekinuli sudjelovanje u ispitivanju bilo kada prije 384. tjedna zbog postizanja protokolom definirane mjere ishoda i oni koji su dovršili 384 tjedna liječenja uključeni su u nazivnik.
English: Viread 163 mg tablets are for use in children.
Croatian: Viread 163 mg tablete namijenjene su primjeni u djece.
English: The HIV and HBV paediatric educational brochures should contain the following key messages:
Croatian: Edukacijske brošure za pedijatrijske bolesnike s HIV-om i HBV-om trebaju sadržavati sljedeće ključne poruke: • Da se u liječenju pedijatrijskih bolesnika preporučuje multidisciplinarni prisup
English: Reductions in BMD have been observed in HBV infected paediatric patients 2 to < 18 years of age.
Croatian: U pedijatrijskih bolesnika u dobi od 2 do < 18 godina zaraženih HBV-om opaženo je smanjenje BMDa.
English: Tell your doctor before taking Viread.
Croatian: Obavijestite liječnika prije nego što počnete uzimati Viread.
English: If renal abnormalities are detected or suspected then consultation with a nephrologist should be obtained to consider interruption of Viread treatment.
Croatian: Ako se otkriju ili se sumnja na abnormalnosti bubrega, potrebno je dobiti stručno mišljenje nefrologa da bi se razmotrio prekid liječenja Vireadom.
English: Your child does not need to take another tablet if they were sick more than 1 hour after taking Viread.
Croatian: Vaše dijete ne treba uzeti drugu tabletu ako je povraćalo nakon što je prošlo više od 1 sata po uzimanju Vireada.
English: Table 4: Efficacy parameters in compensated HBeAg negative patients at week 96, 144, 192, 240, 288 and 384 open-label treatment
Croatian: Tablica 4: Parametri djelotvornosti u kompenziranih HBeAg negativnih bolesnika u 96., 144.,192., 240., 288. i 384. tjednu otvorenog liječenja
English: NA
Croatian: Do
English: Table 5: Efficacy parameters in compensated HBeAg positive patients at week 96, 144, 192, 240, 288 and 384 open-label treatment
Croatian: Tablica 5: Parametri djelotvornosti u kompenziranih HBeAg pozitivnih bolesnika u 96., 144.,192., 240., 288. i 384. tjednu otvorenog liječenja
English: HBV strains expressing the adefovir-associated resistance mutations rtA181V and rtN236T showed a susceptibility to tenofovir ranging from 2.9- to 10-fold that of wild-type virus.
Croatian: HBV koji izražavaju mutacije rtA181V i rtN236T povezane s rezistencijom na adefovir pokazali su 2,9 do 10 puta veću osjetljivost na tenofovir od virusa divljeg tipa.